Shasun Pharmaceuticals Limited

BSE: 524552
₹428.85
▲ 22.50 (5.54%)
Nov. 17, 2015 · BSE · bse_bhavcopy
Quality
—/100
Data unavailable
Valuation
—/100
Data unavailable
Momentum
90/100
Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
Data unavailable.
PE (TTM)
Data unavailable.
Price to Book
Data unavailable.
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
20.0
Relative return vs Sector, qtr %
Data unavailable.
Free Cash Flow
Data unavailable.
EPS Growth (YoY)
Data unavailable.
Net Profit Growth (TTM)
Data unavailable.
Operating Revenue Growth (TTM)
Data unavailable.
Profit Growth (YoY)
Data unavailable.
Revenue Growth (YoY)
Data unavailable.
Current Ratio
Data unavailable (needs a filed half-yearly balance sheet).
Debt to Equity
Data unavailable (needs a filed half-yearly balance sheet).
Interest Coverage
Data unavailable.
Net Margin
Data unavailable.
Operating Margin (EBIT)
Data unavailable.
Operating Margin (TTM)
Data unavailable.
Return on Assets
Data unavailable.
Return on Capital Employed
Data unavailable (needs a filed half-yearly balance sheet).
Return on Equity
Data unavailable (needs a filed half-yearly balance sheet).

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Value and momentum

3 of 4 met
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
5.5%
Low 407.8000 · High 432.0500
1W return
11.9%
Low 384.1500 · High 432.0500
1M return
9.0%
Low 368.4000 · High 432.0500
52W return
100.6%
Low 211.6000 · High 432.0500
Lifetime High ₹428.8500 (Nov. 17, 2015)
Lifetime Low ₹10.6800 (March 12, 2009)

Full price history and technicals →

EMA & SMA

Bullish6
Bearish0
5D
407.4
10D
401.6
20D
397.4
50D
387.8
100D
375.4
200D
351.4

Delivery and volume

Day avg. delivery
35.6%
Week avg. delivery
41.3%
Month avg. delivery
35.8%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

422.90
Pivot
First resistance438.00
Second resistance447.15
Third resistance462.25
First support413.75
Second support398.65
Third support389.50
Day RSI70.3
Day MFI77.0
Day MACD5.43
Day MACD signal4.31

Beta

1M1.42
3M1.43
1Y1.38
3Y1.10

Price change analysis

↑ 9.0%
Over 1 Month
LowHigh
368.40432.05
↑ 6.9%
Over 3 Months
LowHigh
298.00432.05
↑ 26.9%
Over 6 Months
LowHigh
298.00432.05
↑ 100.6%
Over 1 Year
LowHigh
211.60432.05
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Data unavailable.

Shareholding pattern / Ownership

Data unavailable.

Full shareholding pattern →

DateClientDealActionQuantityPriceExchange
10 Feb 2012 SHIVANAND SHANKAR MANKEKAR Block Buy 2,000,000 75.0000 BSE
10 Feb 2012 OM KEDAR INVESTMENTS Block Sell 2,000,000 75.0000 BSE
10 Feb 2012 BP FINTRADE PRIVATE LIMITED Bulk Buy 294,304 77.4700 BSE
10 Feb 2012 BP FINTRADE PRIVATE LIMITED Bulk Sell 299,041 77.7000 BSE
10 Feb 2012 OM KEDAR INVESTMENTS Bulk Sell 2,000,000 75.0000 BSE
10 Feb 2012 SHIVANAND SHANKAR MANKEKAR Bulk Buy 2,000,000 75.0000 BSE
14 Oct 2011 SHASUN FINANCE LTD Bulk Sell 964,000 61.7500 BSE
27 Apr 2011 PRIVATBANK IHAG ZURICH AG Bulk Sell 300,000 77.8300 BSE
27 Apr 2011 OM KEDAR INVESTMENTS Bulk Buy 494,054 77.2700 BSE
4 Jan 2011 CHANDER KANTA Bulk Sell 242,301 81.1400 BSE

All bulk and block deals →

Last 12 months ₹1.00 per share
Dividend yield 0.23%
Ex-dateSubjectPer share (₹)Record date
4 Aug 2015 Annual General Meeting/ Interim Dividend - Re 1/- Per Share (Purpose Revised) 1.0000 —
30 Jul 2014 Annual General Meeting / Dividend - Re 1/- Per Share 1.0000 —
23 Jul 2013 Annual General Meeting / Dividend - Rs 1.50/- Per Share 1.5000 —
23 Jul 2012 Annual General Meeting / Dividend Rs 0.40 Per Share 0.4000 —
21 Mar 2012 Interim Dividend Rs.2/- Per Share (Purpose Revised) 2.0000 22 Mar 2012
20 Jul 2011 Annual General Meeting And Dividend Re.0.30 Per Share 0.3000 —
23 Jul 2010 Annual General Meeting And Dividend Re.1/- Per Share 1.0000 —

Corporate Actions

Full history (14 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from SHASUN CHEMICALS & DRUGS LTD. to Shasun Pharmaceuticals Limited
14 Sep 2009OTHERAnnual General Meeting
17 Jul 2008AGMAgm/Div-Re.1 Per Share
13 Jul 2007AGMAgm/Div-Re.0.90 Per Sh
5 Feb 2007OTHERInt Div-Re.0.80 Per Sh

All corporate actions →

Corporate Announcements

All 123 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
17 Nov 2015 Updates Shasun Pharmaceuticals Limited has informed the Exchange that there was a fire accident at New production block during trial & commissioning in Cuddalore API facility on November 16, 2015. Company regrets to inform the sad demise of one worker in the accident. One more injured employee has been admitted in the hospital for treatment. The Company has informed the government authorities about the same and investigating the root cause of the accident.The damage on account of fire is being assessed for which the company has adequate insurance cover. However there will not be any significant loss of revenue or production due to the above accident.
16 Nov 2015 Press Release Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 16, 2015 titled "Shasun Pharmaceuticals receives USFDA approval for Carisoprodol Tablets".
6 Nov 2015 Record Date Strides Arcolab Limited has informed the Exchange that as approved by the Board of Directors of the Strides Acrolab Limited by a resolution passed on November 05, 2015, has fixed Record Date as November 19, 2015 for the purpose of determining the names of the shareholders of Shasun Pharmaceuticals Limited who will be entitled to shares in the Strides Acrolab Limited (as consideration under the Scheme of the Amalgamation), in the exchange ratio of 5 (five) equity shares of Rs. 10/- each of Strides for every 16 (sixteen) equity shares of Rs. 2/- each held in the Shasun Pharmaceuticals Limited.
27 Oct 2015 Press Release Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 27, 2015 titled "Shasun Pharmaceuticals Ltd announces strong Q2 FY 16 results".
27 Oct 2015 Financial Result Updates Shasun Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Sep-2015.
19 Oct 2015 Trading Window Shasun Pharmaceuticals Limited has informed the Exchange that as per the provisions of the Company's Code for Prevention of Insider Trading, the trading window for designated employees of the Company closed from September 10, 2015 to October 29, 2015 (both days inclusive).
13 Oct 2015 Outcome of Board Meeting Shasun Pharmaceuticals Limited has informed the Exchange that the Board at its meeting held October 13, 2015 has allotted 31,600 equity shares of the face value of Rs.2 each under the ESOP Scheme.The paid up share capital of the Company has increased from Rs.13,44,47,704/ - consisting of 6,72,23,852 equity shares to Rs.13,45,10,904/- consisting of 6,72,55,452 equity shares.
25 Aug 2015 Annual General Meeting Updates Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of Minutes of Annual General Meeting of the Company held on August 12, 2015.
14 Aug 2015 Disclosure of Voting Pattern - Clause 35A Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of voting results of Annual General Meeting of the Company held on August 12, 2015, along with a copy of Scrutinizer's Report pursuant to Clause 35A of the Listing Agreement.
30 Jul 2015 Dividend Shasun Pharmaceuticals Limited has informed the Exchange that The Board at its meeting held on July 30, 2015 has approved the following: 1. Interim Dividend of 50% (Rs. 1 per share) on the equity shares of face value of Rs.2/- each.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

Data unavailable.

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

  • RSI in overbought territory (70.3)

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Shasun Pharmaceuticals Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.